Swiss healthtech startup Aeon has announced the completion of a new seed funding round aimed at scaling its Artificial Intelligence-driven preventive diagnostic platform. Though the exact amount was not disclosed, the funding is intended to fuel Aeon´s expansion beyond its current Swiss base into new markets, including Germany and the United Kingdom. The company leverages advanced tools integrating MRI scans, blood biomarkers, and genetic data, with the goal of identifying chronic disease risks long before symptoms emerge.
Aeon´s core value proposition is its commitment to shifting healthcare from treatment to prevention. By blending full-body imaging, blood testing, and genetic assessments, the startup´s platform offers a holistic view of patient health. Artificial Intelligence algorithms analyze the data to uncover hidden risks, allowing for early intervention and potentially significant reductions in long-term healthcare costs. The company describes its approach as an all-in-one solution that moves routine check-ups into a new era of insight and action.
A major breakthrough for Aeon came with the recent decision by Swiss health insurers to reimburse up to 80% of the startup´s services—a rare accomplishment in the preventive care space. Traditionally, patients have had to pay out-of-pocket for such forward-looking diagnostics, erecting a major barrier to access. The insurance agreement marks a shift in policy and financial incentives, making Aeon´s offering far more accessible to the broader public. With the new funding, Aeon plans to open at least ten new clinics across Switzerland, Germany, and the UK, aiming to set a continental standard for preventive healthcare. As chronic diseases continue to dominate healthcare costs and outcomes worldwide, Aeon´s model could become a template for more proactive, cost-effective care that detects and mitigates risks before they turn into crises.
